{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:24:03Z","timestamp":1760646243805},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1756-0500-7-688","type":"journal-article","created":{"date-parts":[[2014,10,3]],"date-time":"2014-10-03T17:01:12Z","timestamp":1412355672000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9*3 and ABCC2 -24C\u2009>\u2009T variants: a case report"],"prefix":"10.1186","volume":"7","author":[{"given":"Henriette E","family":"Meyer zu Schwabedissen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Siegmund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heyo K","family":"Kroemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens D","family":"Rollnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,10,3]]},"reference":[{"key":"3210_CR1","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.transproceed.2006.12.009","volume":"39","author":"S Sadoni","year":"2007","unstructured":"Sadoni S, Kaczmarek I, Delgado O, Schmockel M, Reichart B, Meiser B: Fluvastatin as co-medication in heart transplant recipients with elevated creatine-kinase. Transplant Proc. 2007, 39: 558-559. 10.1016\/j.transproceed.2006.12.009.","journal-title":"Transplant Proc"},{"key":"3210_CR2","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2217\/pgs.09.85","volume":"10","author":"JE Keskitalo","year":"2009","unstructured":"Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M: Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics. 2009, 10: 1617-1624. 10.2217\/pgs.09.85.","journal-title":"Pharmacogenomics"},{"key":"3210_CR3","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.2217\/pgs.13.135","volume":"14","author":"N Mirosevic Skvrce","year":"2013","unstructured":"Mirosevic Skvrce N, Bozina N, Zibar L, Barisic I, Pejnovic L, Macolic Sarinic V: CYP2C9 and ABCG2 polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a case-control study. Pharmacogenomics. 2013, 14: 1419-1431. 10.2217\/pgs.13.135.","journal-title":"Pharmacogenomics"},{"key":"3210_CR4","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1124\/dmd.105.009175","volume":"34","author":"N Ishiguro","year":"2006","unstructured":"Ishiguro N, Maeda K, Kishimoto W, Saito A, Harada A, Ebner T, Roth W, Igarashi T, Sugiyama Y: Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos. 2006, 34: 1109-1115. 10.1124\/dmd.105.009175.","journal-title":"Drug Metab Dispos"},{"key":"3210_CR5","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1124\/dmd.107.018903","volume":"36","author":"N Ishiguro","year":"2008","unstructured":"Ishiguro N, Maeda K, Saito A, Kishimoto W, Matsushima S, Ebner T, Roth W, Igarashi T, Sugiyama Y: Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide. Drug Metab Dispos. 2008, 36: 796-805. 10.1124\/dmd.107.018903.","journal-title":"Drug Metab Dispos"},{"key":"3210_CR6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/bdd.699","volume":"31","author":"J Weiss","year":"2010","unstructured":"Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Boger RH, Haefeli WE, Benndorf RA: Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010, 31: 150-161. 10.1002\/bdd.699.","journal-title":"Biopharm Drug Dispos"},{"key":"3210_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1124\/dmd.112.046292","volume":"41","author":"T Cabaleiro","year":"2013","unstructured":"Cabaleiro T, Roman M, Ochoa D, Talegon M, Prieto-Perez R, Wojnicz A, Lopez-Rodriguez R, Novalbos J, Abad-Santos F: Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. Drug Metab Dispos. 2013, 41: 224-229. 10.1124\/dmd.112.046292.","journal-title":"Drug Metab Dispos"},{"key":"3210_CR8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2133\/dmpk.22.267","volume":"22","author":"E Kamiyama","year":"2007","unstructured":"Kamiyama E, Yoshigae Y, Kasuya A, Takei M, Kurihara A, Ikeda T: Inhibitory effects of angiotensin receptor blockers on CYP2C9 activity in human liver microsomes. Drug Metab Pharmacokinet. 2007, 22: 267-275. 10.2133\/dmpk.22.267.","journal-title":"Drug Metab Pharmacokinet"},{"key":"3210_CR9","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1056\/NEJMoa0801936","volume":"359","author":"E Link","year":"2008","unstructured":"Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R: SLCO1B1 variants and statin-induced myopathy\u2013a genomewide study. N Engl J Med. 2008, 359: 789-799.","journal-title":"N Engl J Med"},{"key":"3210_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/tpj.2009.54","volume":"10","author":"SP Romaine","year":"2010","unstructured":"Romaine SP, Bailey KM, Hall AS, Balmforth AJ: The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J. 2010, 10: 1-11. 10.1038\/tpj.2009.54.","journal-title":"Pharmacogenomics J"},{"key":"3210_CR11","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0009-9236(03)00121-8","volume":"74","author":"J Kirchheiner","year":"2003","unstructured":"Kirchheiner J, Kudlicz D, Meisel C, Bauer S, Meineke I, Roots I, Brockmoller J: Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther. 2003, 74: 186-194. 10.1016\/S0009-9236(03)00121-8.","journal-title":"Clin Pharmacol Ther"},{"key":"3210_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.tox.2009.08.013","volume":"278","author":"SF Zhou","year":"2010","unstructured":"Zhou SF, Zhou ZW, Huang M: Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology. 2010, 278: 165-188. 10.1016\/j.tox.2009.08.013.","journal-title":"Toxicology"},{"key":"3210_CR13","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.phrs.2006.12.009","volume":"55","author":"P Zuccaro","year":"2007","unstructured":"Zuccaro P, Mombelli G, Calabresi L, Baldassarre D, Palmi I, Sirtori CR: Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacol Res. 2007, 55: 310-317. 10.1016\/j.phrs.2006.12.009.","journal-title":"Pharmacol Res"},{"key":"3210_CR14","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1177\/009127000004001204","volume":"40","author":"J Stangier","year":"2000","unstructured":"Stangier J, Su CA, Hendriks MG, van Lier JJ, Sollie FA, Oosterhuis B, Jonkman JH: Steady-state pharmacodynamics and pharmacokinetics of warfarin in the presence and absence of telmisartan in healthy male volunteers. J Clin Pharmacol. 2000, 40: 1331-1337.","journal-title":"J Clin Pharmacol"},{"key":"3210_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/clpt.2009.219","volume":"87","author":"HK Kroemer","year":"2010","unstructured":"Kroemer HK, Meyer zu Schwabedissen HE: A piece in the puzzle of personalized medicine. Clin Pharmacol Ther. 2010, 87: 19-20. 10.1038\/clpt.2009.219.","journal-title":"Clin Pharmacol Ther"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-0500-7-688.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:35:33Z","timestamp":1689554133000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/1756-0500-7-688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,3]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["3210"],"URL":"https:\/\/doi.org\/10.1186\/1756-0500-7-688","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,3]]},"assertion":[{"value":"10 May 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"688"}}